MP
CORT icon

Mangrove Partners’s Corcept Therapeutics CORT Stock Holding History

Mangrove Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-9,499
Closed -$697K – 191
2025
Q2 		$697K Buy
+9,499
New +$689K 0.07% 111

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Mangrove Partners's CORT Position: Q3 2025 in Review

Mangrove Partners sold out of Corcept Therapeutics (CORT) in Q3 2025, closing a stake of 9,499 shares — an estimated $697K sold.

Mangrove Partners first reported a position in CORT in Q2 2025 and held it in 1 quarter. The position peaked at $697K in Q2 2025. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

  • Mangrove Partners reported no remaining Corcept Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mangrove Partners sold 9,499 Corcept Therapeutics shares in Q3 2025, an estimated $697K.
  • Mangrove Partners first reported a position in Corcept Therapeutics in Q2 2025 and held it in 1 quarter.
  • Mangrove Partners's Corcept Therapeutics position peaked at $697K in Q2 2025.
  • 429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on Mangrove Partners's 13F filing for Q3 2025, filed 14 Nov 2025.